Early research (Phase 1)Study completedNCT03032107What this trial is testingPembrolizumab In Combination With Trastuzumab-DM1Who this might be right forBreast Cancer Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05596409What this trial is testingELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyWho this might be right forMetastatic Breast Cancer Stemline Therapeutics, Inc. 61
Testing effectiveness (Phase 2)Study completedNCT01105312What this trial is testingPanobinostat and Letrozole in Treating Patients With Metastatic Breast CancerWho this might be right forBreast Cancer Alliance for Clinical Trials in Oncology 28
Early research (Phase 1)Active Not RecruitingNCT03939897What this trial is testingTesting the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerWho this might be right forAnatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic HER2-Negative Breast Carcinoma+2 more National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Study completedNCT02971761What this trial is testingPembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerWho this might be right forAndrogen Receptor PositiveEstrogen Receptor NegativeHER2/Neu Negative+3 more City of Hope Medical Center 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06578286What this trial is testingARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXdWho this might be right forBreast Cancer Fudan University 44
Testing effectiveness (Phase 2)Looking for participantsNCT05955170What this trial is testingTucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast CancerWho this might be right forHER2-positive Breast Cancer Institut Curie 66
Large-scale testing (Phase 3)UnknownNCT03080805What this trial is testingPyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)Who this might be right forHER2 Positive Metastatic Breast Cancer Jiangsu HengRui Medicine Co., Ltd. 240
Early research (Phase 1)Ended earlyNCT01149356What this trial is testingRO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerWho this might be right forEstrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more National Cancer Institute (NCI) 15
Early research (Phase 1)Study completedNCT03330561What this trial is testingPRS-343 in HER2-Positive Solid TumorsWho this might be right forHER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more Pieris Pharmaceuticals, Inc. 85
Testing effectiveness (Phase 2)UnknownNCT05335473What this trial is testingIribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor FailureWho this might be right forHR Positive HER2 Negative Advanced Breast Cancer Henan Cancer Hospital 87
Large-scale testing (Phase 3)Looking for participantsNCT07518173What this trial is testingBL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerWho this might be right forHER2-positive Breast Cancer Sichuan Baili Pharmaceutical Co., Ltd. 596
Testing effectiveness (Phase 2)Looking for participantsNCT05800275What this trial is testingCapecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseWho this might be right forLeptomeningeal MetastasisLeptomeningeal DiseaseHER2-positive Metastatic Breast Cancer UNICANCER 30
Large-scale testing (Phase 3)Active Not RecruitingNCT01805271What this trial is testingSafety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone TherapyWho this might be right forPrimary Non-metastatic Breast CancerWho Remain Disease-free UNICANCER 1,278
Testing effectiveness (Phase 2)Study completedNCT02258451What this trial is testingStudy of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast CancerWho this might be right forBreast Neoplasms Bayer 283
Not applicableNot Yet RecruitingNCT06950671What this trial is testingRole of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical StudyWho this might be right forBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage III+1 more Rahma Esam Salama Esawi 1
Large-scale testing (Phase 3)Ended earlyNCT02213744What this trial is testingMM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsWho this might be right forBreast CancerHER2 Positive Breast Cancer Merrimack Pharmaceuticals 113
Post-approval studies (Phase 4)WithdrawnNCT03988114What this trial is testingAbemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWho this might be right forMetastatic Breast Cancer Eli Lilly and Company
Large-scale testing (Phase 3)Active Not RecruitingNCT07386938What this trial is testingThe Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerWho this might be right forLocally Advanced Breast CancerMetastatic Breast Cancer R-Pharm 246
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322What this trial is testingDurvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Who this might be right forER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status UNICANCER 172